Az ACE-gátlók antiatheroscleroticus hatása

Translated title of the contribution: The anti-atherosclerotic effect of ace inhibitor drugs

Research output: Contribution to journalArticle

Abstract

Based on animal and human research data, it is likely that renin-angiotensin-aldosteron system has an important role in the pathogenesis and progression of atherosclerosis. It has been demonstrated in several large clinical trials that ACE inhibitors reduce the risk of ischemic events in patients with left ventricular dysfunction. Whereas some benefits of ACE inhibitors may be related to the lowering of blood pressure, other specific effects on vasculature have also been proposed. ACE inhibitors appear to possess unique cardioprotective and vasculo-protective properties even for patients without hypertension or left ventricular dysfunction. Recent data suggest that most patient with atherosclerotic cardiovascular disease should be considered for ACE inhibitor therapy, unless they are intolerant or have contraindication for the drug. The goal of this article is to review the data from clinical trials that support the anti-atherosclerotic and antiischemic effects of ACE inhibitors.

Original languageHungarian
Pages (from-to)180-186
Number of pages7
JournalLege Artis Medicinae
Volume11
Issue number3
Publication statusPublished - 2001

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Pharmaceutical Preparations
Left Ventricular Dysfunction
Clinical Trials
Renin-Angiotensin System
Atherosclerosis
Cardiovascular Diseases
Blood Pressure
Hypertension
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az ACE-gátlók antiatheroscleroticus hatása. / Czuriga, I.

In: Lege Artis Medicinae, Vol. 11, No. 3, 2001, p. 180-186.

Research output: Contribution to journalArticle

@article{98f2825250314938b2a10609d9db9fe2,
title = "Az ACE-g{\'a}tl{\'o}k antiatheroscleroticus hat{\'a}sa",
abstract = "Based on animal and human research data, it is likely that renin-angiotensin-aldosteron system has an important role in the pathogenesis and progression of atherosclerosis. It has been demonstrated in several large clinical trials that ACE inhibitors reduce the risk of ischemic events in patients with left ventricular dysfunction. Whereas some benefits of ACE inhibitors may be related to the lowering of blood pressure, other specific effects on vasculature have also been proposed. ACE inhibitors appear to possess unique cardioprotective and vasculo-protective properties even for patients without hypertension or left ventricular dysfunction. Recent data suggest that most patient with atherosclerotic cardiovascular disease should be considered for ACE inhibitor therapy, unless they are intolerant or have contraindication for the drug. The goal of this article is to review the data from clinical trials that support the anti-atherosclerotic and antiischemic effects of ACE inhibitors.",
keywords = "ACE inhibitors, Atherosclerosis, Clinical trials, Ischemia, Vasoprotection",
author = "I. Czuriga",
year = "2001",
language = "Hungarian",
volume = "11",
pages = "180--186",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "3",

}

TY - JOUR

T1 - Az ACE-gátlók antiatheroscleroticus hatása

AU - Czuriga, I.

PY - 2001

Y1 - 2001

N2 - Based on animal and human research data, it is likely that renin-angiotensin-aldosteron system has an important role in the pathogenesis and progression of atherosclerosis. It has been demonstrated in several large clinical trials that ACE inhibitors reduce the risk of ischemic events in patients with left ventricular dysfunction. Whereas some benefits of ACE inhibitors may be related to the lowering of blood pressure, other specific effects on vasculature have also been proposed. ACE inhibitors appear to possess unique cardioprotective and vasculo-protective properties even for patients without hypertension or left ventricular dysfunction. Recent data suggest that most patient with atherosclerotic cardiovascular disease should be considered for ACE inhibitor therapy, unless they are intolerant or have contraindication for the drug. The goal of this article is to review the data from clinical trials that support the anti-atherosclerotic and antiischemic effects of ACE inhibitors.

AB - Based on animal and human research data, it is likely that renin-angiotensin-aldosteron system has an important role in the pathogenesis and progression of atherosclerosis. It has been demonstrated in several large clinical trials that ACE inhibitors reduce the risk of ischemic events in patients with left ventricular dysfunction. Whereas some benefits of ACE inhibitors may be related to the lowering of blood pressure, other specific effects on vasculature have also been proposed. ACE inhibitors appear to possess unique cardioprotective and vasculo-protective properties even for patients without hypertension or left ventricular dysfunction. Recent data suggest that most patient with atherosclerotic cardiovascular disease should be considered for ACE inhibitor therapy, unless they are intolerant or have contraindication for the drug. The goal of this article is to review the data from clinical trials that support the anti-atherosclerotic and antiischemic effects of ACE inhibitors.

KW - ACE inhibitors

KW - Atherosclerosis

KW - Clinical trials

KW - Ischemia

KW - Vasoprotection

UR - http://www.scopus.com/inward/record.url?scp=0035026108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035026108&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0035026108

VL - 11

SP - 180

EP - 186

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 3

ER -